Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Multi- and Extensively Drug Resistant Mycobacterium tuberculosis in South Africa: a Molecular Analysis of Historical Isolates.

Maningi NE, Daum LT, Rodriguez JD, Said HM, Peters RPH, Sekyere JO, Fischer GW, Chambers JP, Fourie PB.

J Clin Microbiol. 2018 Apr 25;56(5). pii: e01214-17. doi: 10.1128/JCM.01214-17. Print 2018 May.

2.

The impact of implementing a Xpert MTB/RIF algorithm on drug-sensitive pulmonary tuberculosis: a retrospective analysis.

Rees K, Muditambi N, Maswanganyi M, Railton J, McIntyre JA, Struthers HE, Fourie PB, Peters RPH.

Epidemiol Infect. 2018 Jan;146(2):246-255. doi: 10.1017/S0950268817002746. Epub 2017 Dec 6.

PMID:
29208074
3.

Xpert(®) MTB/RIF detection of Mycobacterium tuberculosis from sputum collected in molecular transport medium.

Daum LT, Fourie PB, Peters RP, Rodriguez JD, Worthy SA, Khubbar M, Bhattacharyya S, Gradus MS, Mboneni T, Marubini EE, Helm C, Chambers JP, Fischer GW.

Int J Tuberc Lung Dis. 2016 Aug;20(8):1118-24. doi: 10.5588/ijtld.15.0990.

PMID:
27393549
4.

Field evaluation of a novel preservation medium to transport sputum specimens for molecular detection of Mycobacterium tuberculosis in a rural African setting.

Omar SV, Peters RP, Ismail NA, Jonkman K, Dreyer AW, Said HM, Gwala T, Ismail N, Fourie PB.

Trop Med Int Health. 2016 Jun;21(6):776-82. doi: 10.1111/tmi.12701. Epub 2016 May 16.

5.

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

Hennig S, Svensson EM, Niebecker R, Fourie PB, Weiner MH, Bonora S, Peloquin CA, Gallicano K, Flexner C, Pym A, Vis P, Olliaro PL, McIlleron H, Karlsson MO.

J Antimicrob Chemother. 2016 May;71(5):1330-40. doi: 10.1093/jac/dkv470. Epub 2016 Jan 31.

6.

Correction for Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy.

Durham PG, Zhang Y, German N, Mortensen N, Dhillon J, Mitchison DA, Fourie PB, Hickey AJ.

Mol Pharm. 2015 Oct 5;12(10):3782. doi: 10.1021/acs.molpharmaceut.5b00673. Epub 2015 Sep 22. No abstract available.

PMID:
26394135
7.

Improved Detection by Next-Generation Sequencing of Pyrazinamide Resistance in Mycobacterium tuberculosis Isolates.

Maningi NE, Daum LT, Rodriguez JD, Mphahlele M, Peters RP, Fischer GW, Chambers JP, Fourie PB.

J Clin Microbiol. 2015 Dec;53(12):3779-83. doi: 10.1128/JCM.01179-15. Epub 2015 Sep 16.

8.

Laboratory evaluation of a specimen transport medium for downstream molecular processing of sputum samples to detect Mycobacterium tuberculosis.

Omar SV, Peters RP, Ismail NA, Dreyer AW, Said HM, Gwala T, Ismail N, Fourie PB.

J Microbiol Methods. 2015 Oct;117:57-63. doi: 10.1016/j.mimet.2015.07.010. Epub 2015 Jul 14.

PMID:
26183764
9.

Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected].

Durham PG, Zhang Y, German N, Mortensen N, Dhillon J, Mitchison DA, Fourie PB, Hickey AJ.

Mol Pharm. 2015 Aug 3;12(8):2574-81. doi: 10.1021/acs.molpharmaceut.5b00118. Epub 2015 Jul 1. Erratum in: Mol Pharm. 2015 Oct 5;12(10):3782.

PMID:
26098136
10.

Molecular detection of Mycobacterium tuberculosis from sputum transported in PrimeStore(®) from rural settings.

Daum LT, Peters RP, Fourie PB, Jonkman K, Worthy SA, Rodriguez JD, Ismail NA, Omar SV, Fischer GW.

Int J Tuberc Lung Dis. 2015 May;19(5):552-7. doi: 10.5588/ijtld.14.0769.

PMID:
25868023
11.

Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: a discussion of the adaptive licensure concept.

Rustomjee R, Lockhart S, Shea J, Fourie PB, Hindle Z, Steel G, Hussey G, Ginsberg A, Brennan MJ.

Tuberculosis (Edinb). 2014 Mar;94(2):178-82. doi: 10.1016/j.tube.2013.11.002. Epub 2013 Dec 8.

12.

Next-generation sequencing for identifying pyrazinamide resistance in Mycobacterium tuberculosis.

Daum LT, Fourie PB, Bhattacharyya S, Ismail NA, Gradus S, Maningi NE, Omar SV, Fischer GW.

Clin Infect Dis. 2014 Mar;58(6):903-4. doi: 10.1093/cid/cit811. Epub 2013 Dec 12. No abstract available.

PMID:
24336821
13.

Persister populations of Mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media.

Dhillon J, Fourie PB, Mitchison DA.

J Antimicrob Chemother. 2014 Feb;69(2):437-40. doi: 10.1093/jac/dkt357. Epub 2013 Sep 26.

PMID:
24072170
14.

Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis.

Hickey AJ, Misra A, Fourie PB.

J Pharm Sci. 2013 Nov;102(11):3900-7. doi: 10.1002/jps.23705. Epub 2013 Aug 20. Review.

PMID:
23963705
15.

Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.

Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E.

Antimicrob Agents Chemother. 2013 Jun;57(6):2613-9. doi: 10.1128/AAC.02346-12. Epub 2013 Mar 25.

16.

"Proof-of-concept" evaluation of an automated sputum smear microscopy system for tuberculosis diagnosis.

Lewis JJ, Chihota VN, van der Meulen M, Fourie PB, Fielding KL, Grant AD, Dorman SE, Churchyard GJ.

PLoS One. 2012;7(11):e50173. doi: 10.1371/journal.pone.0050173. Epub 2012 Nov 29.

17.

Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice.

Verma RK, Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, Gupta P, Gupta UD, Cholo M, Anderson R, Fourie PB, Misra A.

Antimicrob Agents Chemother. 2013 Feb;57(2):1050-2. doi: 10.1128/AAC.01897-12. Epub 2012 Nov 26.

18.

Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains.

Daum LT, Rodriguez JD, Worthy SA, Ismail NA, Omar SV, Dreyer AW, Fourie PB, Hoosen AA, Chambers JP, Fischer GW.

J Clin Microbiol. 2012 Dec;50(12):3831-7. doi: 10.1128/JCM.01893-12. Epub 2012 Sep 12.

19.

Clinical trials of TB vaccines: harmonization and cooperation.

Mahomed H, Fourie PB.

Tuberculosis (Edinb). 2012 Mar;92 Suppl 1:S21-4. doi: 10.1016/S1472-9792(12)70008-2.

PMID:
22441155
20.

Clofazimine: current status and future prospects.

Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R.

J Antimicrob Chemother. 2012 Feb;67(2):290-8. doi: 10.1093/jac/dkr444. Epub 2011 Oct 20. Review.

PMID:
22020137
21.

Inhaled drug therapy for treatment of tuberculosis.

Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K, Fourie PB, Colombo P.

Tuberculosis (Edinb). 2011 Jan;91(1):71-81. doi: 10.1016/j.tube.2010.08.009. Epub 2010 Sep 27. Review.

PMID:
20875771
22.

Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.

Zvada SP, Van Der Walt JS, Smith PJ, Fourie PB, Roscigno G, Mitchison D, Simonsson US, McIlleron HM.

Antimicrob Agents Chemother. 2010 Aug;54(8):3390-4. doi: 10.1128/AAC.00345-10. Epub 2010 Jun 1.

23.

The near future: improving the activity of rifamycins and pyrazinamide.

Mitchison DA, Fourie PB.

Tuberculosis (Edinb). 2010 May;90(3):177-81. doi: 10.1016/j.tube.2010.03.005. Epub 2010 Apr 9. Review.

PMID:
20382083
24.

High diversity of Mycobacterium tuberculosis genotypes in South Africa and preponderance of mixed infections among ST53 isolates.

Stavrum R, Mphahlele M, Ovreås K, Muthivhi T, Fourie PB, Weyer K, Grewal HM.

J Clin Microbiol. 2009 Jun;47(6):1848-56. doi: 10.1128/JCM.02167-08. Epub 2009 Apr 22.

25.

Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.

Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsåker T, Muthivhi T, Weyer K, Fourie PB, Grewal HM.

J Clin Microbiol. 2008 Oct;46(10):3459-64. doi: 10.1128/JCM.00973-08. Epub 2008 Aug 27.

26.

Spray drying TB vaccines for pulmonary administration.

Fourie PB, Germishuizen WA, Wong YL, Edwards DA.

Expert Opin Biol Ther. 2008 Jul;8(7):857-63. doi: 10.1517/14712598.8.7.857 .

PMID:
18564902
27.

Acquired rifamycin resistance: pharmacology and biology.

Wallis RS, Weyer K, Fourie PB.

Expert Rev Anti Infect Ther. 2008 Apr;6(2):223-30. doi: 10.1586/14787210.6.2.223. Review.

PMID:
18380604
28.

Immunization by a bacterial aerosol.

Garcia-Contreras L, Wong YL, Muttil P, Padilla D, Sadoff J, Derousse J, Germishuizen WA, Goonesekera S, Elbert K, Bloom BR, Miller R, Fourie PB, Hickey A, Edwards D.

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4656-60. doi: 10.1073/pnas.0800043105. Epub 2008 Mar 14.

29.

Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers.

McIlleron H, Norman J, Kanyok TP, Fourie PB, Horton J, Smith PJ.

J Antimicrob Chemother. 2007 Dec;60(6):1398-401. Epub 2007 Oct 20.

PMID:
17951604
30.

Activity of 7-methyljuglone derivatives against Mycobacterium tuberculosis and as subversive substrates for mycothiol disulfide reductase.

Mahapatra A, Mativandlela SP, Binneman B, Fourie PB, Hamilton CJ, Meyer JJ, van der Kooy F, Houghton P, Lall N.

Bioorg Med Chem. 2007 Dec 15;15(24):7638-46. Epub 2007 Sep 6.

PMID:
17888665
31.

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, Edwards D.

Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6. Epub 2007 May 21.

32.

Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs.

Gabriels GA, McIlleron H, Smith PJ, Folb PI, Fourie PB.

Int J Tuberc Lung Dis. 2007 Feb;11(2):181-8.

PMID:
17263289
33.

Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis.

Bapela NB, Lall N, Fourie PB, Franzblau SG, Van Rensburg CE.

Phytomedicine. 2006 Nov;13(9-10):630-5. Epub 2006 Sep 20.

PMID:
16987644
34.

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.

Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, Roscigno G, Norman J, McIlleron H, Mitchison DA.

Am J Respir Crit Care Med. 2005 Jul 1;172(1):128-35. Epub 2005 Apr 1.

PMID:
15805182
35.

Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis.

Johnson JL, Nunn AJ, Fourie PB, Ormerod LP, Mugerwa RD, Mwinga A, Chintu C, Ngwira B, Onyebujoh P, Zumla A.

Int J Tuberc Lung Dis. 2004 Nov;8(11):1348-54.

PMID:
15581204
36.

Early bactericidal activity of antituberculosis agents.

Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW, Maritz JS, Fourie PB.

Expert Rev Anti Infect Ther. 2003 Jun;1(1):141-55. Review.

PMID:
15482107
37.

Antimicrobial activity of clofazimine is not dependent on mycobacterial C-type phospholipases.

Bopape MC, Steel HC, Cockeran R, Matlola NM, Fourie PB, Anderson R.

J Antimicrob Chemother. 2004 Jun;53(6):971-4. Epub 2004 Apr 29.

PMID:
15117926
38.

Whither Mycobacterium vaccae--encore.

Fourie PB, Ellner JJ, Johnson JL.

Lancet. 2002 Oct 5;360(9339):1032-3. No abstract available.

PMID:
12383977
39.
40.

Evaluation of a rapid test for HIV antibodies in saliva and blood.

Webber LM, Swanevelder C, Grabow WO, Fourie PB.

S Afr Med J. 2000 Oct;90(10):1004-7.

PMID:
11081107
41.

Mycobacterium bovis as a zoonosis in the Kruger National Park, South Africa.

Weyer K, Fourie PB, Dürrheim D, Lancaster J, Haslöv K, Bryden H.

Int J Tuberc Lung Dis. 1999 Dec;3(12):1113-9.

PMID:
10599016
43.

Proposed minimum registration requirements for fixed-dose combination anti-tuberculosis drugs.

Fourie PB.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S362-7; discussion S381-7.

PMID:
10593719
44.

The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.

McIlleron H, Gabriels G, Smith PJ, Fourie PB, Ellard GA.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S329-35; discussion S351-2.

PMID:
10593713
45.

Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.

Pillai G, Fourie PB, Padayatchi N, Onyebujoh PC, McIlleron H, Smith PJ, Gabriels G.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S309-16; discussion S317-21.

PMID:
10593710
46.

Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.

Ellard GA, Fourie PB.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S301-8; discussion S317-21. Review.

PMID:
10593709
47.

Universal pattern of RpoB gene mutations among multidrug-resistant isolates of Mycobacterium tuberculosis complex from Africa.

Schilke K, Weyer K, Bretzel G, Amthor B, Brandt J, Sticht-Groh V, Fourie PB, Haas WH.

Int J Tuberc Lung Dis. 1999 Jul;3(7):620-6.

PMID:
10423225
48.

Procedures for developing a simple scoring method based on unsophisticated criteria for screening children for tuberculosis.

Fourie PB, Becker PJ, Festenstein F, Migliori GB, Alcaide J, Antunes M, Auregan G, Beyers N, Carvalho JM, Cruz JR, Fanning EA, Gie R, Huong ND, Leitch AG.

Int J Tuberc Lung Dis. 1998 Feb;2(2):116-23.

PMID:
9562121
49.

Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa.

Haas WH, Schilke K, Brand J, Amthor B, Weyer K, Fourie PB, Bretzel G, Sticht-Groh V, Bremer HJ.

Antimicrob Agents Chemother. 1997 Jul;41(7):1601-3.

50.

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis.

McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, Fourie PB.

Am J Respir Crit Care Med. 1996 Nov;154(5):1462-7.

PMID:
8912765

Supplemental Content

Loading ...
Support Center